MicroVue™ C3a Plus EIA

The MicroVue C3a Plus Enzyme Immunoassay is for the measurement of C3a in plasma and serum.


Product Specifications

Citations64
Specimen

Serum/EDTA Plasma 10 μL

LLOQ0.023 ng/mL
ULOQ2.531 ng/mL
Assay Time2.5 hours
Cross Reactivity

African Green Monkey, Cynomolgous monkey, Rhesus monkey

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog NumberA031
Catalog Number (CE)A032
Size96 wells/test
Price (USD)$725.00
Price (EURO)640,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

The MicroVue C3a Plus Enzyme Immunoassay is for the measurement of C3a in plasma and serum.

Size96 wells/test
Form

96 well plate with 12 eight-well strips in a resealable foil pouch

SpecimenSerum/EDTA Plasma 10 μL
Limit of Detection (LOD)0.012 ng/mL
Lower Limit of Quantitation (LLOQ)0.023 ng/mL
Upper Limit of Quantitation (ULOQ)2.531 ng/mL
Intra Assay4.5–5.3%
Inter Assay5.9–19.6%
Standards5
Controls2
Sample Values

Serum 71.0–589.2 ng/mL, EDTA Plasma 33.8–268.1 ng/mL

Assay Time2.5 hours
Cross Reactivity

African Green Monkey, Cynomolgous monkey, Rhesus monkey

Storage

Store the unopened kit at 2°C to 8°C. Refer to Product Insert for additional storage details.

Background

Under normal conditions, activation of the classical, alternative, or lectin complement pathways results in the formation of a C3 convertase multi-molecular enzyme capable of cleaving C3 to C3a and C3b. C3a is a low molecular weight (approximately 9kD) protein fragment of 77 amino acids. C3a is rapidly metabolized by the serum enzyme carboxypeptidase N to a more stable, 76 amino acid form, C3a des-Arg. For convenience, both forms will be referred to as “C3a” for purposes of this documentation. The MicroVue C3a Plus assay, a rapid, highly specific and quantitative procedure for measuring C3a levels, is designed for investigations into the role or status of complement pathway activation in numerous research settings, and for monitoring the generation of C3a in vivo or in vitro. C3a has been shown to increase vascular permeability, to be spasmogenic and chemotactic, and to induce the release of pharmacologically active mediators from a number of cell types. The role of C3a in the pathogenesis of inflammatory reactions seen in gram-negative bacterial sepsis, trauma, ischemic heart disease, cerebral ischemia, post dialysis syndrome and several autoimmune diseases (including rheumatoid arthritis, lupus erythematosus, and acute glomerulonephritis) is well documented.

Citations

TitleYearApplicationsSample SpeciesSampleSample Details

Decrease in multiple complement protein levels is associated with the development of islet autoimmunity and type 1 diabetes.

2023ELISAHuman

Plasma

Diabetes

Reduced binding of apoE4 to complement factor H promotes amyloid-β oligomerization and neuroinflammation.

2023ELISAHuman

Supernatent

Latex beads with poE2, apoE3, or apoE4

Complement Activation in Patients With Heat-Related Illnesses: Soluble CD59 Is a Novel Biomarker Indicating Severity of Heat-Related Illnesses.

2022ELISAHuman

Plasma

Heat-related illnesses

Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study.

2022ELISAHuman

Plasma

COVID-19

Sex and Age-Related Differences in Complement Factors Among Patients With Intermediate Age-Related Macular Degeneration.

2022ELISAHuman

Plasma

Age-Related Macular Degeneration

Plasma C4 level was associated with mortality, cardiovascular and cerebrovascular complications in hemodialysis patients.

2022ELISAHuman

Plasma

Hemodialysis

A randomized diet-induced weight-loss intervention reduces plasma complement C3: Possible implication for endothelial dysfunction.

2022ELISAHuman

Plasma

Obesity

C3a and C5b-9 Differentially Predict COVID-19 Progression and Outcome.

2022ELISAHuman

Plasma

COVID-19

The Role of Complement in Microangiopathic Lesions of IgA Nephropathy.

2022ELISAHuman

Serum

IgA Nephropathy

Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis.

2022ELISAHuman

Urine

AAV, FSGS, IgAN, MN, and LN

The Inflammatory Feed-Forward Loop Triggered by the Complement Component C3 as a Potential Target in Endometriosis.

2021ELISAHuman

Peritoneal fluid (w/ Endometriosis)

N/A

von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.

2021ELISAHuman

Plasma

C3G

Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking.

2021ELISAHuman

Plasma

N/A

Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19.

2021ELISAHuman

Plasma

Cancer, COVID-19

Air Bubbles Activate Complement and Trigger Hemostasis and C3-Dependent Cytokine Release Ex Vivo in Human Whole Blood.

2021ELISAHuman

Plasma

N/A

Complement levels at admission as a reflection of coronavirus disease 2019 (COVID-19) severity state.

2021ELISAHuman

Serum

COVID-19

von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.

2021ELISAHuman

Urine

C3G

Decreased immune response in monkeys administered a human T-effector cell agonist (OX40) antibody.

2020ELISACynomolgus Monkey

Plasma, Serum

T-effector cell agonist (OX40) antibody

Complement Activation Profile of Patients With Primary Focal Segmental Glomerulosclerosis.

2020ELISAHuman

Plasma

FSGS

Effect of Aerobic and Anaerobic Exercise on the Complement System of Proteins in Healthy Young Males.

2020ELISAHuman

Plasma

N/A

Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy.

2020ELISAHuman

Plasma

COVID-19

Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression.

2020ELISAHuman

Plasma

COVID-19

Interrelationship between ADAMTS13 activity, von Willebrand factor, and complement activation in remission from immune-mediated trhrombotic thrombocytopenic purpura.

2020ELISAHuman

Plasma

Immune‐mediated thrombotic thrombocytopenic purpura

Complement Activation in the Vitreous of Patients With Proliferative Diabetic Retinopathy.

2020ELISAHuman

Plasma, Vitreous Humor

Proliferative Diabetic Retinopathy

Subvisible Particles in IVIg Formulations Activate Complement in Human Serum.

2020ELISAHuman

Serum

IVIg formulations

Complement Activation Profile of Patients With Primary Focal Segmental Glomerulosclerosis.

2020ELISAHuman

Serum

FSGS

In vitro comparison of three percutaneous atrial septal defect closure devices for endothelialisation and haemocompatibility.

2020ELISAHuman

Serum

N/A

Cloaking Silica Nanoparticles with Functional Protein Coatings for Reduced Complement Activation and Cellular Uptake.

2020ELISAHuman

Serum

SiNP coated proteins

Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis.

2020ELISAHuman

Serum

Lupus Nephritis, Thrombotic Microangiopathy

Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis.

2020ELISAHuman

Urine

Lupus Nephritis, Thrombotic Microangiopathy

Early local activation of complement in aqueous humour of patients with age-related macular degeneration.

2019ELISAHuman

Aqueous humour

Age-Related Macular Degeneration

Complement factor H contributes to mortality in humans and mice with bacterial meningitis.

2019ELISAHuman

CSF

Bacterial meningitis

Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

2019ELISAHuman

Plasma

ANCA-AAV

Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura.

2019ELISAHuman

Plasma

aHUS

Complete kinetic follow-up of symptoms and complement parameters during a hereditary angioedema attack.

2017ELISAHuman

Plasma

Hereditary Angioedema

Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia

2017ELISAHuman

Plasma

N/A

Platelets are activated in ANCA-associated vasculitis via thrombin-PARs pathway and can activate the alternative complement pathway

2017ELISAHuman

Plasma

ANCA-AAV

Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma

2017ELISAHuman

Plasma

N/A

Complement Protein C3 Suppresses Axon Growth and Promotes Neuron Loss

2017ELISAMouse

Neuron Cells

N/A

Pentraxin 3 recruits complement factor H to protect against oxidative stress-induced complement and inflammasome overactivation.

2016ELISAHuman

ARPE-19 Cells

N/A

Platelet-borne complement proteins and their role in platelet–bacteria interactions

2016ELISAHuman

Plasma

N/A

Complement Factor H Expressed by Retinal Pigment Epithelium Cells Can Suppress Neovascularization of Human Umbilical Vein Endothelial Cells: An in vitro Study

2015ELISAHuman

ARPE-19 Cells

N/A

Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis

2015ELISAHuman

Plasma

N/A

Complement Factor H Expressed by Retinal Pigment Epithelium Cells Can Suppress Neovascularization of Human Umbilical Vein Endothelial Cells: An in vitro Study

2015ELISAHuman

Serum

N/A

Genetic engineering strategies to prevent the effects of antibody and complement on xenogeneic chondrocytes

2015ELISAHuman

Serum

Porcine articular chondrocytes

Autocrine Effects of Tumor-Derived Complement

2014ELISACell Culture

SKOV3ip1 cells

N/A

Cerebrospinal fluid inflammatory markers in patients with Listeria monocytogenes meningitis

2014ELISAHuman

CSF

Listeria meningitis

Complement activation in patients with neuromyelitis optica

2014ELISAHuman

Plasma

Neuromyelitis optica

Clinicopathological characteristics and outcomes of Chinese patients with scanty immune deposits lupus nephritis: a large cohort study from a single center

2014ELISAHuman

Plasma

Lupus Nephritis

Associations between abnormal rod-mediated dark adaptation and health and functioning in older adults with normal macular health

2014ELISAHuman

Plasma

N/A

Genetic variation and cerebrospinal fluid levels of mannose binding lectin in pneumococcal meningitis patients.

2013ELISAHuman

CSF

N/A

Complement activation in pediatric patients with recurrent acute otitis media

2013ELISAHuman

Ear Fluid (MEE)

N/A

Borrelia valaisiana resist complement-mediated killing independently of the recruitment of immune regulators and inactivation of complement components

2013ELISAHuman

Serum

Borrelia valaisiana incubated

Complement activation in pediatric patients with recurrent acute otitis media

2013ELISAHuman

Serum

N/A

Zonulin as prehaptoglobin2 regulates lung permeability and activates the complement system

2013ELISAHuman

Serum

N/A

Human factor H-related protein 2 (CFHR2) regulates complement activation

2013ELISAHuman

Serum

N/A

Assessment of endothelium and inflammatory response at the onset of reperfusion injury in hand surgery

2012ELISAHuman

Plasma

N/A

A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function

2012ELISAHuman

Serum

GEnCs and HUVEC exposed

Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1β

2011ELISAHuman

Peripheral blood mononuclear cells

N/A

Absence of Gal epitope prolongs survival of swine lungs in an ex vivo model of hyperacute rejection

2011ELISAHuman

Plasma

N/A

Complement C3 serum levels in anorexia nervosa: a potential biomarker for the severity of disease

2011ELISAHuman

Serum

N/A

Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor

2010ELISAHuman, Primate

Serum

N/A

Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide

2002ELISACynomolgus Monkey

Serum

N/A

Complement activation during painful crisis in sickle cell anemia

1995ELISAHuman

Plasma

Sickel Cell Anemia